Drugs / CD20 monoclonal antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05258136 | Jun 2021 → Jun 2023 | Epstein-Barr virus infection, hemophagocytic syndrome, post-transplant lymphoproliferative disease | Beijing Friendship Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD20 monoclonal antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05258136 ↗ |
| Modality | Monoclonal antibody | “CD20 monoclonal antibody injection” NCT05258136 ↗ |
| Route | Intravenous | “was intravenously infused once a week” NCT05258136 ↗ |